ARTICLE | Company News
KSB, Sosei TransMID deal
May 28, 2002 7:00 AM UTC
KS Biomedix (LSE:KSB) granted Sosei (Tokyo, Japan) Japanese rights to its Phase II TransMID treatment for recurrent high grade glioma. KSB will manufacture and sell TransMID materials for Sosei, which...